A heterologous prime-boost vaccination strategy comprising the francisella tularensis live vaccine strain capB mutant and recombinant attenuated listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge

Infection and Immunity

Volumn 81, Issue 5, 2013, Pages 1550-1561

  Jia, Qingmei ^a   Bowen, Richard ^b   Sahakian, Jacob ^a   Dillon, Barbara Jane ^a   Horwitz, Marcus A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRANCISELLA TULARENSIS LIVE VACCINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; LIVE VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRANCISELLA TULARENSIS; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; LD 50; LISTERIA MONOCYTOGENES; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN CELL; SURVIVAL RATE; SURVIVAL TIME; VACCINATION; WEIGHT CHANGE;

AEROSOLS; ANALYSIS OF VARIANCE; ANIMALS; BACTERIAL VACCINES; CYTOKINES; FEMALE; FRANCISELLA TULARENSIS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED BALB C; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES; TULAREMIA; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84877837322     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01013-12     Document Type: Article

References (62)

1. Sjostedt A. 2007. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N. Y. Acad. Sci. 1105:1-29.
2. Johansson A, Celli J, Conlan W, Elkins KL, Forsman M, Keim PS, Larsson P, Manoil C, Nano FE, Petersen JM, Sjostedt A. 2010. Objections to the transfer of Francisella novicida to the subspecies rank of Francisella tularensis. Int. J. Syst. Evol. Microbiol. 60:1717-1718.
3. Bell JF, Owen CR, Larson CL. 1955. Virulence of bacterium tularense. I. A study of the virulence of bacterium tularense in mice, guinea pigs, and rabbits. J. Infect. Dis. 97:162-166.
4. Day WC, Berendt RF. 1972. Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis. Infect. Immun. 5:77-82.
5. Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. 1961. Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. 107: 689-701.
6. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 702-714.
7. Matyas BT, Nieder HS, Telford SR, 3rd. 2007. Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics. Ann. N. Y. Acad. Sci. 1105:351-377.
8. Feldman KA, Enscore RE, Lathrop SL, Matyas BT, McGuill M, Schriefer ME, Stiles-Enos D, Dennis DT, Petersen LR, Hayes EB. 2001. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N. Engl. J. Med. 345:1601-1606.
9. Svensson K, Larsson P, Johansson D, Bystrom M, Forsman M, Johans-son A. 2005. Evolution of subspecies of Francisella tularensis. J. Bacteriol. 187:3903-3908.
10. Forslund AL, Kuoppa K, Svensson K, Salomonsson E, Johansson A, Bystrom M, Oyston PC, Michell SL, Titball RW, Noppa L, Frithz- Lindsten E, Forsman M, Forsberg A. 2006. Direct repeat-mediated deletion of a type IV pilin gene results in major virulence attenuation of Francisella tularensis. Mol. Microbiol. 59:1818-1830.
11. Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, Johansson A, Kelly J, Lindgren H, Svensson K, Zingmark C, Conlan W, Sjostedt A. 2005. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect. Immun. 73:8345-8352.
12. Salomonsson E, Kuoppa K, Forslund AL, Zingmark C, Golovliov I, Sjostedt A, Noppa L, Forsberg A. 2009. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect. Immun. 77:3424-3431.
13. McCrumb FR. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25:262-267.
14. Eigelsbach HT, Downs CM. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87:415-425.
15. De Pascalis R, Chou AY, Bosio CM, Huang CY, Follmann DA, Elkins KL. 2012. Development of functional and molecular correlates of vaccineinduced protection for a model intracellular pathogen, F. tularensis LVS. PLoS Pathog. 8:e1002494. doi:10.1371/journal.ppat.1002494.
16. Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA. 2010. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect. Immun. 78:4341-4355.
17. Clemens DL, Lee BY, Horwitz MA. 2005. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect. Immun. 73:5892-5902.
18. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjostedt A. 2003. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect. Immun. 71:5940-5950.
19. Pamer EG. 2004. Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4:812-823.
20. Bruhn KW, Craft N, Miller JF. 2007. Listeria as a vaccine vector. Microbes Infect. 9:1226-1235.
21. Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. 2009. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized type A F. tularensis. Vaccine 27:1216-1229.
22. Golovliov I, Ericsson M, Sandstrom G, Tarnvik A, Sjostedt A. 1997. Identification of proteins of Francisella tularensis induced during growth in macrophages and cloning of the gene encoding a prominently induced 23-kilodalton protein. Infect. Immun. 65:2183-2189.
23. Lai XH, Golovliov I, Sjostedt A. 2004. Expression of IglC is necessary for intracellular growth and induction of apoptosis in murine macrophages by Francisella tularensis. Microb. Pathog. 37:225-230.
24. Santic M, Molmeret M, Klose KE, Jones S, Kwaik YA. 2005. The Francisella tularensis pathogenicity island protein IglC and its regulator MglA are essential for modulating phagosome biogenesis and subsequent bacterial escape into the cytoplasm. Cell. Microbiol. 7:969-979.
25. Barker JR, Klose KE. 2007. Molecular and genetic basis of pathogenesis in Francisella tularensis. Ann. N. Y. Acad. Sci. 1105:138-159.
26. Havlasova J, Hernychova L, Halada P, Pellantova V, Krejsek J, Stulik J, Macela A, Jungblut PR, Larsson P, Forsman M. 2002. Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics 2:857-867.
27. Havlasova J, Hernychova L, Brychta M, Hubalek M, Lenco J, Larsson P, Lundqvist M, Forsman M, Krocova Z, Stulik J, Macela A. 2005. Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 5:2090-2103.
28. Janovska S, Pavkova I, Hubalek M, Lenco J, Macela A, Stulik J. 2007. Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Immunol. Lett. 108:151-159.
29. Clemens DL, Lee BY, Horwitz MA. 2012. O-antigen-deficient Francisella tularensis live vaccine strain mutants are ingested via an aberrant form of looping phagocytosis and show altered kinetics of intracellular trafficking in human macrophages. Infect. Immun. 80:952-967.
30. Maier TM, Havig A, Casey M, Nano FE, Frank DW, Zahrt TC. 2004. Construction and characterization of a highly efficient Francisella shuttle plasmid. Appl. Environ. Microbiol. 70:7511-7519.
31. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, Guglani L, Alcorn JF, Strawbridge H, Park SM, Onishi R, Nyugen N, Walter MJ, Pociask D, Randall TD, Gaffen SL, Iwakura Y, Kolls JK, Khader SA. 2009. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 31:799-810.
32. Shen H, Harris G, Chen W, Sjostedt A, Ryden P, Conlan W. 2010. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One 5:e13349. doi:10.1371/journal.pone.0013349.
33. Mara-Koosham G, Hutt JA, Lyons CR, Wu TH. 2011. Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains. Infect. Immun. 79:1770-1778.
34. Cowley SC, Elkins KL. 2011. Immunity to francisella. Front. Microbiol. 2:26.
35. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
36. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di Carlo P, Titone L, Galati D, Bocchino M, Matarese A, Salerno A, Sanduzzi A, Franken WP, Ottenhoff TH, Dieli F. 2010. Multifunctional CD4() T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40:2211-2220.
37. Derrick SC, Yabe IM, Yang A, Morris SL. 2011. Vaccine-induced antituberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29:2902-2909.
38. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J. Immunol. 181:4955-4964.
39. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, Rosenkrands I, Andersen P. 2009. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182:8047-8055.
40. Conlan WJ, Shen H, Kuolee R, Zhao X, Chen W. 2005. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-dependent mechanism. Vaccine 23:2477-2485.
41. Sjostedt A, North RJ, Conlan JW. 1996. The requirement of tumour necrosis factor-alpha and interferon-gamma for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142:1369-1374.
42. Nano FE, Schmerk C. 2007. The Francisella pathogenicity island. Ann. N. Y. Acad. Sci. 1105:122-137.
43. Eyles JE, Unal B, Hartley MG, Newstead SL, Flick-Smith H, Prior JL, Oyston PC, Randall A, Mu Y, Hirst S, Molina DM, Davies DH, Milne T, Griffin KF, Baldi P, Titball RW, Felgner PL. 2007. Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 7:2172-2183.
44. Valentino MD, Maben ZJ, Hensley LL, Woolard MD, Kawula TH, Frelinger JA, Frelinger JG. 2011. Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology 132:348-360.
45. Hornick RB, Eigelsbach HT. 1966. Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. 30:532-538.
46. Chen W, Shen H, Webb A, KuoLee R, Conlan JW. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21:3690-3700.
47. Fortier AH, Slayter MV, Ziemba R, Meltzer MS, Nacy CA. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59:2922-2928.
48. Conlan WJ, Oyston PC. 2007. Vaccines against Francisella tularensis. Ann. N. Y. Acad. Sci. 1105:325-350.
49. Maciag PC, Radulovic S, Rothman J. 2009. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27:3975-3983.
50. Johnson PV, Blair BM, Zeller S, Kotton CN, Hohmann EL. 2011. Attenuated Listeria monocytogenes vaccine vectors expressing influenza Anucleoprotein: preclinical evaluation and oral inoculation of volunteers. Microbiol. Immunol. 55:304-317.
51. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Jr, Eiden JE, Jaffee EM, Laheru DA. 2012. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin. Cancer Res. 18:858-868.
52. Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, Chen W, House RV, Sjostedt A. 2010. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine 28:1824-1831.
53. Lu S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21:346-351.
54. Conlan JW, Shen H, Webb A, Perry MB. 2002. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20:3465-3471.
55. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, Norgard MV. 2008. Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect. Immun. 76:3664-3671.
56. Elkins KL, Cowley SC, Bosio CM. 2007. Innate and adaptive immunity to Francisella. Ann. N. Y. Acad. Sci. 1105:284-324.
57. Eneslatt K, Rietz C, Ryden P, Stoven S, House RV, Wolfraim LA, Tarnvik A, Sjostedt A. 2011. Persistence of cell-mediated immunity three decades after vaccination with the live vaccine strain of Francisella tularensis. Eur. J. Immunol. 41:974-980.
58. Ericsson M, Sandstrom G, Sjostedt A, Tarnvik A. 1994. Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J. Infect. Dis. 170:110-114.
59. Koskela P, Herva E. 1980. Cell-mediated immunity against Francisella tularensis after natural infection. Scand. J. Infect. Dis. 12:281-287.
60. Eneslatt K, Normark M, Bjork R, Rietz C, Zingmark C, Wolfraim LA, Stoven S, Sjostedt A. 2012. Signatures of T cells as correlates of immunity to Francisella tularensis. PLoS One 7:e32367. doi:10.1371/journal.pone .0032367.
61. Connor LM, Harvie MC, Rich FJ, Quinn KM, Brinkmann V, Le Gros G, Kirman JR. 2010. A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur. J. Immunol. 40:2482-2492.
62. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182:1073-1079.